hs-CRP: How to Interpret Your Result

What hs-CRP Actually Measures

High-sensitivity C-reactive protein is an acute-phase reactant produced by the liver in response to interleukin-6 signaling. The "high-sensitivity" label refers to the assay method, not a different protein. Standard CRP tests measure values from roughly 3 to 1 to 000 mg/L to detect overt infection or autoimmune flares. The hs-CRP assay detects concentrations as low as 0.1 mg/L, making it useful for identifying the subtle, chronic inflammation tied to atherosclerosis and metabolic syndrome.

CRP itself does not cause disease. It is a downstream marker of inflammatory cytokine activity. Elevated hs-CRP reflects vascular endothelial activation, adipose tissue inflammation, or both. A 2003 consensus statement from the American Heart Association and Centers for Disease Control established hs-CRP as a validated adjunct biomarker for coronary risk stratification [1]. That framework still anchors current practice. The protein has a half-life of about 19 hours and responds quickly to both pro-inflammatory and anti-inflammatory changes, which is why a single reading can be misleading after a recent cold, dental procedure, or injury.

The test costs between $20 and $50 at most commercial labs. It requires no fasting, though some clinicians prefer a morning draw to minimize diurnal variation. Results typically return within 24 hours.

The Three-Tier Risk Classification

The AHA/CDC framework sorts hs-CRP into three cardiovascular risk tiers: below 1.0 mg/L (low risk), 1.0 to 3.0 mg/L (average risk), and above 3.0 mg/L (high risk). Any value above 10 mg/L should be discarded and retested after two to three weeks, because it likely reflects an acute process rather than baseline vascular inflammation [1].

This classification comes from large population studies. In the Women's Health Study (N=27,939), women in the highest hs-CRP quintile had a relative risk of 2.3 for a first cardiovascular event compared with the lowest quintile over an 8-year follow-up, even after adjusting for LDL cholesterol and other traditional risk factors [2]. The Emerging Risk Factors Collaboration pooled data from 54 prospective studies (N=160,309) and confirmed that hs-CRP concentration was log-linearly associated with coronary heart disease risk, with a hazard ratio of 1.37 per 1-SD higher log-CRP level after adjustment for conventional factors [3].

A common mistake is treating hs-CRP as a standalone diagnostic. It is not. The 2019 ACC/AHA Primary Prevention Guideline recommends hs-CRP testing specifically when a treatment decision about statin therapy remains uncertain after calculating the 10-year atherosclerotic cardiovascular disease (ASCVD) risk score [4]. If your 10-year risk is borderline (5% to 7.5%) or intermediate (7.5% to 20%), a persistently elevated hs-CRP above 2.0 mg/L can tip the decision toward starting a statin.

When hs-CRP Rises Above 3.0 mg/L

A result above 3.0 mg/L that is confirmed on repeat testing signals chronic low-grade inflammation. The most common contributors are visceral adiposity, insulin resistance, smoking, periodontal disease, and obstructive sleep apnea. Less common but clinically relevant causes include subclinical autoimmune conditions, chronic kidney disease, and hormone replacement therapy with oral estrogen.

Adipose tissue is the single largest driver of elevated hs-CRP in the general population. Fat cells secrete interleukin-6 directly, and the relationship is nearly linear with body mass index. A meta-analysis of 51 studies found that each 1-unit increase in BMI was associated with a 0.13 mg/L rise in CRP concentration [5]. The same relationship explains why bariatric surgery produces dramatic hs-CRP reductions. In the Swedish Obese Subjects study, patients who lost a mean of 23% body weight after bariatric procedures saw hs-CRP fall by approximately 50% at 10 years, while the non-surgical control group showed no change [6].

Smoking is the second most modifiable contributor. Current smokers have hs-CRP values roughly 50% to 100% higher than non-smokers. Cessation reduces hs-CRP measurably within 5 years, though the inflammatory signal does not fully normalize for a decade or more [7]. If your hs-CRP is elevated and you smoke, quitting has a larger expected anti-inflammatory effect than any medication.

When hs-CRP Is Below 1.0 mg/L

A low hs-CRP is favorable. It means the liver is producing minimal C-reactive protein, suggesting low systemic inflammatory burden. There is no clinical condition defined by hs-CRP being "too low." Values near the assay's lower limit of detection (0.1 to 0.2 mg/L) are normal and desirable.

Some patients ask whether a very low hs-CRP means their immune system is weak. It does not. CRP is a marker of ongoing inflammation, not immune competence. A person with an hs-CRP of 0.2 mg/L will still mount a strong CRP response during an infection, then return to baseline once the infection clears.

The prognostic value of low hs-CRP was demonstrated in the JUPITER trial. Participants who achieved both an LDL below 70 mg/dL and an hs-CRP below 1.0 mg/L on rosuvastatin had a 65% reduction in vascular events, compared with a 33% reduction in those who only achieved the LDL target [8].

What Medications and Supplements Do to hs-CRP

Statins are the most studied hs-CRP-lowering drugs. In JUPITER (N=17,802), rosuvastatin 20 mg daily reduced hs-CRP by a median of 37% independent of its LDL-lowering effect [8]. The trial was stopped early after a median follow-up of 1.9 years because the statin group had 44% fewer major cardiovascular events. This study was the first to show statin benefit specifically in patients with elevated hs-CRP (above 2.0 mg/L) but normal LDL (below 130 mg/dL).

GLP-1 receptor agonists also reduce hs-CRP. In a post hoc analysis of the STEP-1 trial (N=1,961), semaglutide 2.4 mg weekly reduced hs-CRP by approximately 34% at 68 weeks compared with an 18% reduction in the placebo group, with much of the effect attributable to weight loss [9]. Liraglutide showed similar anti-inflammatory properties in the LEADER cardiovascular outcomes trial [10].

Metformin lowers hs-CRP modestly, in the range of 10% to 20%, likely through its effects on hepatic glucose output and AMPK activation rather than direct anti-inflammatory action [11].

For supplements, omega-3 fatty acids at prescription doses (3.7 to 4 g/day of EPA plus DHA) reduced hs-CRP by about 15% in a pooled analysis of 68 randomized trials [12]. Curcumin supplements (500 to 1 to 000 mg/day) showed a similar magnitude of reduction in a separate meta-analysis of 20 trials, though quality of evidence was low [13]. Over-the-counter fish oil capsules typically contain 300 mg of combined EPA/DHA per capsule, well below the doses studied.

Aspirin does not meaningfully lower hs-CRP despite being an anti-inflammatory drug. Its mechanism targets cyclooxygenase rather than the IL-6/CRP axis.

Lifestyle Interventions That Lower hs-CRP

Weight loss is the most potent non-pharmacologic intervention. A systematic review of 76 studies showed that a 5% to 10% reduction in body weight decreased hs-CRP by 25% to 40% on average, with larger reductions corresponding to greater weight loss [14]. The effect occurs regardless of how the weight is lost: caloric restriction, exercise-induced deficit, or surgical intervention all produce comparable hs-CRP drops per kilogram shed.

Exercise independently lowers hs-CRP even without weight loss, though the effect is smaller. A Cochrane-level meta-analysis of 83 trials found that aerobic exercise programs reduced hs-CRP by a weighted mean difference of 0.63 mg/L, with greater effects at higher baseline CRP levels [15]. Resistance training showed smaller but still significant reductions. The minimum effective dose appears to be roughly 150 minutes per week of moderate-intensity activity, consistent with AHA physical activity guidelines.

Sleep quality matters. Obstructive sleep apnea is independently associated with elevated hs-CRP, and a 2014 meta-analysis showed that CPAP therapy for at least 4 hours per night reduced hs-CRP by 0.4 to 0.8 mg/L in patients with moderate-to-severe OSA [16]. Even in patients without frank apnea, sleeping fewer than 6 hours per night is associated with higher hs-CRP than sleeping 7 to 8 hours.

A Mediterranean dietary pattern reduces hs-CRP by 20% to 30% compared with a typical Western diet. The PREDIMED trial (N=7,447) demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts significantly lowered inflammatory markers, including hs-CRP, over 5 years of follow-up [17].

How to Interpret hs-CRP Alongside Other Labs

hs-CRP is most informative when read alongside a lipid panel, fasting glucose or HbA1c, and a metabolic panel. The combination tells a richer story than any single test.

Dr. Paul Ridker, the lead investigator of the JUPITER trial and a professor at Harvard Medical School, has stated: "Measuring hs-CRP in addition to cholesterol is analogous to measuring both blood pressure and cholesterol. Each provides independent predictive information" [8]. The ACC/AHA guidelines echo this view. They recommend hs-CRP as a "risk-enhancing factor" that can be used alongside coronary artery calcium scoring, ankle-brachial index, and family history to refine risk estimates [4].

A useful clinical pairing is hs-CRP with LDL particle number (LDL-P) or apolipoprotein B. A patient with low LDL-cholesterol but elevated hs-CRP and high LDL-P has residual inflammatory and atherogenic risk that a standard lipid panel might miss. Conversely, a patient with mildly elevated LDL but an hs-CRP below 0.5 mg/L and low Lp(a) may have lower absolute risk than a calculator suggests.

Fibrinogen, another acute-phase reactant, can confirm that an elevated hs-CRP reflects a chronic inflammatory state rather than an isolated spike. If both are elevated on repeat testing, the probability of true underlying inflammation is high. If hs-CRP is elevated but fibrinogen is normal, consider a transient cause such as recent illness or soft-tissue injury.

For patients on GLP-1 receptor agonists or considering them, tracking hs-CRP at baseline, 3 months, and 6 months can quantify the anti-inflammatory response to therapy alongside weight and glycemic metrics. A 30% or greater decline in hs-CRP within the first 3 months suggests a strong systemic anti-inflammatory response.

Retesting Protocol and Common Pitfalls

The AHA/CDC consensus recommends averaging two hs-CRP measurements taken at least 2 weeks apart to establish a reliable baseline [1]. A single elevated value after a cold, a hard workout, or a dental cleaning is not meaningful.

Oral estrogen therapy (but not transdermal estrogen) raises hs-CRP by 30% to 60% due to first-pass hepatic stimulation of CRP synthesis. Women on oral hormone therapy should have their hs-CRP values interpreted with this offset in mind, or ideally switch to a transdermal formulation if cardiovascular risk stratification is the goal. A Women's Health Initiative substudy confirmed that oral conjugated equine estrogens raised hs-CRP significantly, while transdermal estradiol did not [18].

Nonsteroidal anti-inflammatory drugs (NSAIDs) at chronic doses can suppress hs-CRP, potentially masking underlying inflammation. If a patient takes daily ibuprofen or naproxen for arthritis, their hs-CRP may underestimate true inflammatory burden.

Race and sex influence population distributions. hs-CRP values tend to run higher in women than men and higher in Black Americans than White Americans, even after adjusting for BMI and metabolic factors. The MESA study (N=6,814) documented these differences and suggested that race- and sex-specific cutpoints may improve risk prediction, though the AHA/CDC thresholds have not been officially revised [19].

Do not order hs-CRP during acute illness, within 2 weeks of surgery, or during a flare of a known inflammatory condition. These scenarios produce values in the 10 to 200+ mg/L range that tell you nothing about baseline cardiovascular risk. Wait for clinical resolution, then test.